Key takeaways
Tirzepatide (Zepbound) and metformin (Glumetza) are both medications used to help manage conditions related to weight and insulin resistance. While tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used for weight loss and sleep apnea, metformin is a biguanide primarily used for Type 2 diabetes. Tirzepatide is administered as a weekly subcutaneous injection, whereas metformin is taken orally, usually once or twice a day. Tirzepatide is available only as a brand-name medication, while metformin is available in both brand-name and generic forms. Common side effects of tirzepatide include nausea, diarrhea, and stomach pain; metformin can also cause diarrhea and nausea. Tirzepatide can interact with diabetes medications, warfarin (Jantoven, Coumadin), and birth control pills; metformin can also interact with other diabetes medications, as well as alcohol. Additionally, tirzepatide has a risk of thyroid cancer and pancreatitis, while metformin carries a risk of lactic acidosis and low vitamin B12 levels.
